GSK plc (LON:GSK) Declares GBX 15 Dividend

GSK plc (LON:GSK - Get Free Report) declared a dividend on Wednesday, October 30th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, November 14th will be given a dividend of GBX 15 ($0.19) per share on Thursday, January 9th. This represents a yield of 1.03%. The ex-dividend date is Thursday, November 14th. The official announcement can be viewed at this link.

GSK Stock Down 3.0 %

Shares of GSK stock traded down GBX 43 ($0.56) on Wednesday, hitting GBX 1,408.50 ($18.27). 34,693,012 shares of the stock were exchanged, compared to its average volume of 10,265,227. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The firm has a market capitalization of £57.47 billion, a P/E ratio of 1,228.76, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a fifty-two week low of GBX 1,371.40 ($17.78) and a fifty-two week high of GBX 1,823.50 ($23.65). The business has a 50-day moving average of GBX 1,553.14 and a 200 day moving average of GBX 1,598.08.

Insider Transactions at GSK

In other GSK news, insider Jonathan Symonds purchased 7,150 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of GBX 1,394 ($18.08) per share, for a total transaction of £99,671 ($129,258.20). In other news, insider Jonathan Symonds purchased 7,150 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of GBX 1,394 ($18.08) per share, with a total value of £99,671 ($129,258.20). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the firm's stock in a transaction on Monday, September 23rd. The stock was purchased at an average cost of GBX 2,051 ($26.60) per share, for a total transaction of £9,147.46 ($11,862.87). In the last three months, insiders acquired 7,604 shares of company stock worth $10,893,886. 1.61% of the stock is owned by company insiders.

Analyst Ratings Changes

GSK has been the subject of several research reports. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research note on Monday, July 29th. Citigroup lowered their target price on GSK from GBX 2,120 ($27.49) to GBX 1,900 ($24.64) and set a "buy" rating on the stock in a research report on Friday, July 5th. Berenberg Bank reissued a "buy" rating and set a GBX 1,820 ($23.60) price target on shares of GSK in a research report on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a GBX 1,850 ($23.99) price target on shares of GSK in a research note on Tuesday, September 3rd. Finally, Shore Capital reiterated a "buy" rating on shares of GSK in a research note on Wednesday, August 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of GBX 1,842.50 ($23.89).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.